 | • レポートコード：MRC2-11QY08750 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、145ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はパーキンソン病（PD）治療薬のグローバル市場について調査・分析したレポートです。種類別（ドーパミン作動薬、モノアミン酸化酵素阻害剤、アセチルコリンエステラーゼ阻害剤、グルタメート阻害剤）市場規模、用途別（病院、家族）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別パーキンソン病（PD）治療薬の競争状況、市場シェア ・世界のパーキンソン病（PD）治療薬市場：種類別市場規模 2015年-2020年（ドーパミン作動薬、モノアミン酸化酵素阻害剤、アセチルコリンエステラーゼ阻害剤、グルタメート阻害剤） ・世界のパーキンソン病（PD）治療薬市場：種類別市場規模予測 2021年-2026年（ドーパミン作動薬、モノアミン酸化酵素阻害剤、アセチルコリンエステラーゼ阻害剤、グルタメート阻害剤） ・世界のパーキンソン病（PD）治療薬市場：用途別市場規模 2015年-2020年（病院、家族） ・世界のパーキンソン病（PD）治療薬市場：用途別市場規模予測 2021年-2026年（病院、家族） ・北米のパーキンソン病（PD）治療薬市場分析：米国、カナダ ・ヨーロッパのパーキンソン病（PD）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのパーキンソン病（PD）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のパーキンソン病（PD）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのパーキンソン病（PD）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Boehringer Ingelheim、GlaxoSmithKline、Novartis、Teva Pharmaceutical Industries、AbbVie、Abital Pharma、Addex Therapeutics、Biogen、Eisai、Eli Lilly、F. Hoffmann-La Roche、H. Lundbeck、Impax Laboratories、Kyowa Hakko Kirin、Otsuka Pharmaceutical、Pfizer ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.
The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.
Market Analysis and Insights: Global Parkinson’s Disease (PD) Drugs Market
The global Parkinson’s Disease (PD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Parkinson’s Disease (PD) Drugs Scope and Market Size
Parkinson’s Disease (PD) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Parkinson’s Disease (PD) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Parkinson’s Disease (PD) Drugs market is segmented into
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
Segment by Application, the Parkinson’s Disease (PD) Drugs market is segmented into
Hospital
Family
Regional and Country-level Analysis
The Parkinson’s Disease (PD) Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Parkinson’s Disease (PD) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Parkinson’s Disease (PD) Drugs Market Share Analysis
Parkinson’s Disease (PD) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Parkinson’s Disease (PD) Drugs business, the date to enter into the Parkinson’s Disease (PD) Drugs market, Parkinson’s Disease (PD) Drugs product introduction, recent developments, etc.
The major vendors covered:
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer
1 Study Coverage
1.1 Parkinson’s Disease (PD) Drugs Product Introduction
1.2 Market Segments
1.3 Key Parkinson’s Disease (PD) Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Parkinson’s Disease (PD) Drugs Market Size Growth Rate by Type
1.4.2 Dopamine Agonist
1.4.3 Monoamine Oxidase Inhibitors
1.4.4 Acetylcholinesterase Inhibitors
1.4.5 Glutamate Inhibitors
1.5 Market by Application
1.5.1 Global Parkinson’s Disease (PD) Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Family
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Parkinson’s Disease (PD) Drugs Market Size, Estimates and Forecasts
2.1.1 Global Parkinson’s Disease (PD) Drugs Revenue 2015-2026
2.1.2 Global Parkinson’s Disease (PD) Drugs Sales 2015-2026
2.2 Global Parkinson’s Disease (PD) Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Parkinson’s Disease (PD) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Parkinson’s Disease (PD) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Parkinson’s Disease (PD) Drugs Competitor Landscape by Players
3.1 Parkinson’s Disease (PD) Drugs Sales by Manufacturers
3.1.1 Parkinson’s Disease (PD) Drugs Sales by Manufacturers (2015-2020)
3.1.2 Parkinson’s Disease (PD) Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Parkinson’s Disease (PD) Drugs Revenue by Manufacturers
3.2.1 Parkinson’s Disease (PD) Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Parkinson’s Disease (PD) Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Parkinson’s Disease (PD) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Parkinson’s Disease (PD) Drugs Revenue in 2019
3.2.5 Global Parkinson’s Disease (PD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Parkinson’s Disease (PD) Drugs Price by Manufacturers
3.4 Parkinson’s Disease (PD) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Parkinson’s Disease (PD) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Parkinson’s Disease (PD) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Parkinson’s Disease (PD) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Parkinson’s Disease (PD) Drugs Market Size by Type (2015-2020)
4.1.1 Global Parkinson’s Disease (PD) Drugs Sales by Type (2015-2020)
4.1.2 Global Parkinson’s Disease (PD) Drugs Revenue by Type (2015-2020)
4.1.3 Parkinson’s Disease (PD) Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Parkinson’s Disease (PD) Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Parkinson’s Disease (PD) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Parkinson’s Disease (PD) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Parkinson’s Disease (PD) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Parkinson’s Disease (PD) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Parkinson’s Disease (PD) Drugs Market Size by Application (2015-2020)
5.1.1 Global Parkinson’s Disease (PD) Drugs Sales by Application (2015-2020)
5.1.2 Global Parkinson’s Disease (PD) Drugs Revenue by Application (2015-2020)
5.1.3 Parkinson’s Disease (PD) Drugs Price by Application (2015-2020)
5.2 Parkinson’s Disease (PD) Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Parkinson’s Disease (PD) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Parkinson’s Disease (PD) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Parkinson’s Disease (PD) Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Parkinson’s Disease (PD) Drugs by Country
6.1.1 North America Parkinson’s Disease (PD) Drugs Sales by Country
6.1.2 North America Parkinson’s Disease (PD) Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Parkinson’s Disease (PD) Drugs Market Facts & Figures by Type
6.3 North America Parkinson’s Disease (PD) Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Parkinson’s Disease (PD) Drugs by Country
7.1.1 Europe Parkinson’s Disease (PD) Drugs Sales by Country
7.1.2 Europe Parkinson’s Disease (PD) Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Parkinson’s Disease (PD) Drugs Market Facts & Figures by Type
7.3 Europe Parkinson’s Disease (PD) Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Parkinson’s Disease (PD) Drugs by Region
8.1.1 Asia Pacific Parkinson’s Disease (PD) Drugs Sales by Region
8.1.2 Asia Pacific Parkinson’s Disease (PD) Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Parkinson’s Disease (PD) Drugs Market Facts & Figures by Type
8.3 Asia Pacific Parkinson’s Disease (PD) Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Parkinson’s Disease (PD) Drugs by Country
9.1.1 Latin America Parkinson’s Disease (PD) Drugs Sales by Country
9.1.2 Latin America Parkinson’s Disease (PD) Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Parkinson’s Disease (PD) Drugs Market Facts & Figures by Type
9.3 Central & South America Parkinson’s Disease (PD) Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Parkinson’s Disease (PD) Drugs by Country
10.1.1 Middle East and Africa Parkinson’s Disease (PD) Drugs Sales by Country
10.1.2 Middle East and Africa Parkinson’s Disease (PD) Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Parkinson’s Disease (PD) Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Parkinson’s Disease (PD) Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Corporation Information
11.1.2 Boehringer Ingelheim Description and Business Overview
11.1.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Boehringer Ingelheim Parkinson’s Disease (PD) Drugs Products Offered
11.1.5 Boehringer Ingelheim Related Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Description and Business Overview
11.2.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.2.4 GlaxoSmithKline Parkinson’s Disease (PD) Drugs Products Offered
11.2.5 GlaxoSmithKline Related Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Description and Business Overview
11.3.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis Parkinson’s Disease (PD) Drugs Products Offered
11.3.5 Novartis Related Developments
11.4 Teva Pharmaceutical Industries
11.4.1 Teva Pharmaceutical Industries Corporation Information
11.4.2 Teva Pharmaceutical Industries Description and Business Overview
11.4.3 Teva Pharmaceutical Industries Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Teva Pharmaceutical Industries Parkinson’s Disease (PD) Drugs Products Offered
11.4.5 Teva Pharmaceutical Industries Related Developments
11.5 AbbVie
11.5.1 AbbVie Corporation Information
11.5.2 AbbVie Description and Business Overview
11.5.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AbbVie Parkinson’s Disease (PD) Drugs Products Offered
11.5.5 AbbVie Related Developments
11.6 Abital Pharma
11.6.1 Abital Pharma Corporation Information
11.6.2 Abital Pharma Description and Business Overview
11.6.3 Abital Pharma Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Abital Pharma Parkinson’s Disease (PD) Drugs Products Offered
11.6.5 Abital Pharma Related Developments
11.7 Addex Therapeutics
11.7.1 Addex Therapeutics Corporation Information
11.7.2 Addex Therapeutics Description and Business Overview
11.7.3 Addex Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Addex Therapeutics Parkinson’s Disease (PD) Drugs Products Offered
11.7.5 Addex Therapeutics Related Developments
11.8 Biogen
11.8.1 Biogen Corporation Information
11.8.2 Biogen Description and Business Overview
11.8.3 Biogen Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Biogen Parkinson’s Disease (PD) Drugs Products Offered
11.8.5 Biogen Related Developments
11.9 Eisai
11.9.1 Eisai Corporation Information
11.9.2 Eisai Description and Business Overview
11.9.3 Eisai Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Eisai Parkinson’s Disease (PD) Drugs Products Offered
11.9.5 Eisai Related Developments
11.10 Eli Lilly
11.10.1 Eli Lilly Corporation Information
11.10.2 Eli Lilly Description and Business Overview
11.10.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Eli Lilly Parkinson’s Disease (PD) Drugs Products Offered
11.10.5 Eli Lilly Related Developments
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Corporation Information
11.1.2 Boehringer Ingelheim Description and Business Overview
11.1.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Boehringer Ingelheim Parkinson’s Disease (PD) Drugs Products Offered
11.1.5 Boehringer Ingelheim Related Developments
11.12 H. Lundbeck
11.12.1 H. Lundbeck Corporation Information
11.12.2 H. Lundbeck Description and Business Overview
11.12.3 H. Lundbeck Sales, Revenue and Gross Margin (2015-2020)
11.12.4 H. Lundbeck Products Offered
11.12.5 H. Lundbeck Related Developments
11.13 Impax Laboratories
11.13.1 Impax Laboratories Corporation Information
11.13.2 Impax Laboratories Description and Business Overview
11.13.3 Impax Laboratories Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Impax Laboratories Products Offered
11.13.5 Impax Laboratories Related Developments
11.14 Kyowa Hakko Kirin
11.14.1 Kyowa Hakko Kirin Corporation Information
11.14.2 Kyowa Hakko Kirin Description and Business Overview
11.14.3 Kyowa Hakko Kirin Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Kyowa Hakko Kirin Products Offered
11.14.5 Kyowa Hakko Kirin Related Developments
11.15 Otsuka Pharmaceutical
11.15.1 Otsuka Pharmaceutical Corporation Information
11.15.2 Otsuka Pharmaceutical Description and Business Overview
11.15.3 Otsuka Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Otsuka Pharmaceutical Products Offered
11.15.5 Otsuka Pharmaceutical Related Developments
11.16 Pfizer
11.16.1 Pfizer Corporation Information
11.16.2 Pfizer Description and Business Overview
11.16.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.16.4 Pfizer Products Offered
11.16.5 Pfizer Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Parkinson’s Disease (PD) Drugs Market Estimates and Projections by Region
12.1.1 Global Parkinson’s Disease (PD) Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Parkinson’s Disease (PD) Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Parkinson’s Disease (PD) Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Parkinson’s Disease (PD) Drugs Sales Forecast (2021-2026)
12.2.2 North America: Parkinson’s Disease (PD) Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Parkinson’s Disease (PD) Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Parkinson’s Disease (PD) Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Parkinson’s Disease (PD) Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Parkinson’s Disease (PD) Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Parkinson’s Disease (PD) Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Parkinson’s Disease (PD) Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Parkinson’s Disease (PD) Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Parkinson’s Disease (PD) Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Parkinson’s Disease (PD) Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Parkinson’s Disease (PD) Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Parkinson’s Disease (PD) Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Parkinson’s Disease (PD) Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Parkinson’s Disease (PD) Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Parkinson’s Disease (PD) Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Parkinson’s Disease (PD) Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Parkinson’s Disease (PD) Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Parkinson’s Disease (PD) Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Parkinson’s Disease (PD) Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Parkinson’s Disease (PD) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Parkinson's Disease (PD) Drugs Market Segments
Table 2. Ranking of Global Top Parkinson's Disease (PD) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Parkinson's Disease (PD) Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Dopamine Agonist
Table 5. Major Manufacturers of Monoamine Oxidase Inhibitors
Table 6. Major Manufacturers of Acetylcholinesterase Inhibitors
Table 7. Major Manufacturers of Glutamate Inhibitors
Table 8. Global Parkinson's Disease (PD) Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 9. Global Parkinson's Disease (PD) Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 10. Global Parkinson's Disease (PD) Drugs Sales by Regions 2015-2020 (K Pcs)
Table 11. Global Parkinson's Disease (PD) Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Parkinson's Disease (PD) Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Parkinson's Disease (PD) Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 14. Global Parkinson's Disease (PD) Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Parkinson's Disease (PD) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Parkinson's Disease (PD) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Parkinson's Disease (PD) Drugs as of 2019)
Table 17. Parkinson's Disease (PD) Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Parkinson's Disease (PD) Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Parkinson's Disease (PD) Drugs Price (2015-2020) (USD/Pcs)
Table 20. Parkinson's Disease (PD) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Parkinson's Disease (PD) Drugs Product Type
Table 22. Date of International Manufacturers Enter into Parkinson's Disease (PD) Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Parkinson's Disease (PD) Drugs Sales by Type (2015-2020) (K Pcs)
Table 25. Global Parkinson's Disease (PD) Drugs Sales Share by Type (2015-2020)
Table 26. Global Parkinson's Disease (PD) Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Parkinson's Disease (PD) Drugs Revenue Share by Type (2015-2020)
Table 28. Parkinson's Disease (PD) Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 29. Global Parkinson's Disease (PD) Drugs Sales by Application (2015-2020) (K Pcs)
Table 30. Global Parkinson's Disease (PD) Drugs Sales Share by Application (2015-2020)
Table 31. North America Parkinson's Disease (PD) Drugs Sales by Country (2015-2020) (K Pcs)
Table 32. North America Parkinson's Disease (PD) Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Parkinson's Disease (PD) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Parkinson's Disease (PD) Drugs Sales by Type (2015-2020) (K Pcs)
Table 36. North America Parkinson's Disease (PD) Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Parkinson's Disease (PD) Drugs Sales by Application (2015-2020) (K Pcs)
Table 38. North America Parkinson's Disease (PD) Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Parkinson's Disease (PD) Drugs Sales by Country (2015-2020) (K Pcs)
Table 40. Europe Parkinson's Disease (PD) Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Parkinson's Disease (PD) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Parkinson's Disease (PD) Drugs Sales by Type (2015-2020) (K Pcs)
Table 44. Europe Parkinson's Disease (PD) Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Parkinson's Disease (PD) Drugs Sales by Application (2015-2020) (K Pcs)
Table 46. Europe Parkinson's Disease (PD) Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Parkinson's Disease (PD) Drugs Sales by Region (2015-2020) (K Pcs)
Table 48. Asia Pacific Parkinson's Disease (PD) Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Parkinson's Disease (PD) Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Parkinson's Disease (PD) Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Parkinson's Disease (PD) Drugs Sales by Type (2015-2020) (K Pcs)
Table 52. Asia Pacific Parkinson's Disease (PD) Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Parkinson's Disease (PD) Drugs Sales by Application (2015-2020) (K Pcs)
Table 54. Asia Pacific Parkinson's Disease (PD) Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Parkinson's Disease (PD) Drugs Sales by Country (2015-2020) (K Pcs)
Table 56. Latin America Parkinson's Disease (PD) Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Parkinson's Disease (PD) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Parkinson's Disease (PD) Drugs Sales by Type (2015-2020) (K Pcs)
Table 60. Latin America Parkinson's Disease (PD) Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Parkinson's Disease (PD) Drugs Sales by Application (2015-2020) (K Pcs)
Table 62. Latin America Parkinson's Disease (PD) Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Parkinson's Disease (PD) Drugs Sales by Country (2015-2020) (K Pcs)
Table 64. Middle East and Africa Parkinson's Disease (PD) Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Parkinson's Disease (PD) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Parkinson's Disease (PD) Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Parkinson's Disease (PD) Drugs Sales by Type (2015-2020) (K Pcs)
Table 68. Middle East and Africa Parkinson's Disease (PD) Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Parkinson's Disease (PD) Drugs Sales by Application (2015-2020) (K Pcs)
Table 70. Middle East and Africa Parkinson's Disease (PD) Drugs Sales Market Share by Application (2015-2020)
Table 71. Boehringer Ingelheim Corporation Information
Table 72. Boehringer Ingelheim Description and Major Businesses
Table 73. Boehringer Ingelheim Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 74. Boehringer Ingelheim Product
Table 75. Boehringer Ingelheim Recent Development
Table 76. GlaxoSmithKline Corporation Information
Table 77. GlaxoSmithKline Description and Major Businesses
Table 78. GlaxoSmithKline Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 79. GlaxoSmithKline Product
Table 80. GlaxoSmithKline Recent Development
Table 81. Novartis Corporation Information
Table 82. Novartis Description and Major Businesses
Table 83. Novartis Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 84. Novartis Product
Table 85. Novartis Recent Development
Table 86. Teva Pharmaceutical Industries Corporation Information
Table 87. Teva Pharmaceutical Industries Description and Major Businesses
Table 88. Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 89. Teva Pharmaceutical Industries Product
Table 90. Teva Pharmaceutical Industries Recent Development
Table 91. AbbVie Corporation Information
Table 92. AbbVie Description and Major Businesses
Table 93. AbbVie Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 94. AbbVie Product
Table 95. AbbVie Recent Development
Table 96. Abital Pharma Corporation Information
Table 97. Abital Pharma Description and Major Businesses
Table 98. Abital Pharma Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 99. Abital Pharma Product
Table 100. Abital Pharma Recent Development
Table 101. Addex Therapeutics Corporation Information
Table 102. Addex Therapeutics Description and Major Businesses
Table 103. Addex Therapeutics Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 104. Addex Therapeutics Product
Table 105. Addex Therapeutics Recent Development
Table 106. Biogen Corporation Information
Table 107. Biogen Description and Major Businesses
Table 108. Biogen Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 109. Biogen Product
Table 110. Biogen Recent Development
Table 111. Eisai Corporation Information
Table 112. Eisai Description and Major Businesses
Table 113. Eisai Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 114. Eisai Product
Table 115. Eisai Recent Development
Table 116. Eli Lilly Corporation Information
Table 117. Eli Lilly Description and Major Businesses
Table 118. Eli Lilly Parkinson's Disease (PD) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 119. Eli Lilly Product
Table 120. Eli Lilly Recent Development
Table 121. F. Hoffmann-La Roche Corporation Information
Table 122. F. Hoffmann-La Roche Description and Major Businesses
Table 123. F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 124. F. Hoffmann-La Roche Product
Table 125. F. Hoffmann-La Roche Recent Development
Table 126. H. Lundbeck Corporation Information
Table 127. H. Lundbeck Description and Major Businesses
Table 128. H. Lundbeck Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 129. H. Lundbeck Product
Table 130. H. Lundbeck Recent Development
Table 131. Impax Laboratories Corporation Information
Table 132. Impax Laboratories Description and Major Businesses
Table 133. Impax Laboratories Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 134. Impax Laboratories Product
Table 135. Impax Laboratories Recent Development
Table 136. Kyowa Hakko Kirin Corporation Information
Table 137. Kyowa Hakko Kirin Description and Major Businesses
Table 138. Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 139. Kyowa Hakko Kirin Product
Table 140. Kyowa Hakko Kirin Recent Development
Table 141. Otsuka Pharmaceutical Corporation Information
Table 142. Otsuka Pharmaceutical Description and Major Businesses
Table 143. Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 144. Otsuka Pharmaceutical Product
Table 145. Otsuka Pharmaceutical Recent Development
Table 146. Pfizer Corporation Information
Table 147. Pfizer Description and Major Businesses
Table 148. Pfizer Parkinson's Disease (PD) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 149. Pfizer Product
Table 150. Pfizer Recent Development
Table 151. Global Parkinson's Disease (PD) Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 152. Global Parkinson's Disease (PD) Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 153. Global Parkinson's Disease (PD) Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 154. Global Parkinson's Disease (PD) Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 155. North America: Parkinson's Disease (PD) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 156. North America: Parkinson's Disease (PD) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 157. Europe: Parkinson's Disease (PD) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 158. Europe: Parkinson's Disease (PD) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 159. Asia Pacific: Parkinson's Disease (PD) Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 160. Asia Pacific: Parkinson's Disease (PD) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 161. Latin America: Parkinson's Disease (PD) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 162. Latin America: Parkinson's Disease (PD) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 163. Middle East and Africa: Parkinson's Disease (PD) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 164. Middle East and Africa: Parkinson's Disease (PD) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 165. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 166. Key Challenges
Table 167. Market Risks
Table 168. Main Points Interviewed from Key Parkinson's Disease (PD) Drugs Players
Table 169. Parkinson's Disease (PD) Drugs Customers List
Table 170. Parkinson's Disease (PD) Drugs Distributors List
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. Parkinson's Disease (PD) Drugs Product Picture
Figure 2. Global Parkinson's Disease (PD) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Dopamine Agonist Product Picture
Figure 4. Monoamine Oxidase Inhibitors Product Picture
Figure 5. Acetylcholinesterase Inhibitors Product Picture
Figure 6. Glutamate Inhibitors Product Picture
Figure 7. Global Parkinson's Disease (PD) Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospital
Figure 9. Family
Figure 10. Parkinson's Disease (PD) Drugs Report Years Considered
Figure 11. Global Parkinson's Disease (PD) Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Parkinson's Disease (PD) Drugs Sales 2015-2026 (K Pcs)
Figure 13. Global Parkinson's Disease (PD) Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Parkinson's Disease (PD) Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Parkinson's Disease (PD) Drugs Sales Market Share by Region in 2019
Figure 16. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Region in 2019
Figure 18. Global Parkinson's Disease (PD) Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Parkinson's Disease (PD) Drugs Revenue in 2019
Figure 20. Parkinson's Disease (PD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Parkinson's Disease (PD) Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Parkinson's Disease (PD) Drugs Sales Market Share by Type in 2019
Figure 23. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Type in 2019
Figure 25. Global Parkinson's Disease (PD) Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Parkinson's Disease (PD) Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Parkinson's Disease (PD) Drugs Sales Market Share by Application in 2019
Figure 28. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Parkinson's Disease (PD) Drugs Revenue Market Share by Application in 2019
Figure 30. North America Parkinson's Disease (PD) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 31. North America Parkinson's Disease (PD) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Parkinson's Disease (PD) Drugs Sales Market Share by Country in 2019
Figure 33. North America Parkinson's Disease (PD) Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 35. U.S. Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 36. Canada Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. Canada Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. North America Parkinson's Disease (PD) Drugs Market Share by Type in 2019
Figure 39. North America Parkinson's Disease (PD) Drugs Market Share by Application in 2019
Figure 40. Europe Parkinson's Disease (PD) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 41. Europe Parkinson's Disease (PD) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 42. Europe Parkinson's Disease (PD) Drugs Sales Market Share by Country in 2019
Figure 43. Europe Parkinson's Disease (PD) Drugs Revenue Market Share by Country in 2019
Figure 44. Germany Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 45. Germany Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 46. France Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. France Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. U.K. Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. U.K. Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. Italy Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. Italy Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Russia Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Russia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Europe Parkinson's Disease (PD) Drugs Market Share by Type in 2019
Figure 55. Europe Parkinson's Disease (PD) Drugs Market Share by Application in 2019
Figure 56. Asia Pacific Parkinson's Disease (PD) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 57. Asia Pacific Parkinson's Disease (PD) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 58. Asia Pacific Parkinson's Disease (PD) Drugs Sales Market Share by Region in 2019
Figure 59. Asia Pacific Parkinson's Disease (PD) Drugs Revenue Market Share by Region in 2019
Figure 60. China Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 61. China Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 62. Japan Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. Japan Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. South Korea Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. South Korea Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. India Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. India Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Australia Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. Australia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Taiwan Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Taiwan Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Indonesia Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Indonesia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Thailand Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Thailand Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Malaysia Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Malaysia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Philippines Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Philippines Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Vietnam Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Vietnam Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Asia Pacific Parkinson's Disease (PD) Drugs Market Share by Type in 2019
Figure 83. Asia Pacific Parkinson's Disease (PD) Drugs Market Share by Application in 2019
Figure 84. Latin America Parkinson's Disease (PD) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 85. Latin America Parkinson's Disease (PD) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 86. Latin America Parkinson's Disease (PD) Drugs Sales Market Share by Country in 2019
Figure 87. Latin America Parkinson's Disease (PD) Drugs Revenue Market Share by Country in 2019
Figure 88. Mexico Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 89. Mexico Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 90. Brazil Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Brazil Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Argentina Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Argentina Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Latin America Parkinson's Disease (PD) Drugs Market Share by Type in 2019
Figure 95. Latin America Parkinson's Disease (PD) Drugs Market Share by Application in 2019
Figure 96. Middle East and Africa Parkinson's Disease (PD) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 97. Middle East and Africa Parkinson's Disease (PD) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 98. Middle East and Africa Parkinson's Disease (PD) Drugs Sales Market Share by Country in 2019
Figure 99. Middle East and Africa Parkinson's Disease (PD) Drugs Revenue Market Share by Country in 2019
Figure 100. Turkey Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 101. Turkey Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 102. Saudi Arabia Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Saudi Arabia Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. U.A.E Parkinson's Disease (PD) Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. U.A.E Parkinson's Disease (PD) Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Middle East and Africa Parkinson's Disease (PD) Drugs Market Share by Type in 2019
Figure 107. Middle East and Africa Parkinson's Disease (PD) Drugs Market Share by Application in 2019
Figure 108. North America Parkinson's Disease (PD) Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 109. North America Parkinson's Disease (PD) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 110. Europe Parkinson's Disease (PD) Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. Europe Parkinson's Disease (PD) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Asia Pacific Parkinson's Disease (PD) Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Asia Pacific Parkinson's Disease (PD) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Latin America Parkinson's Disease (PD) Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Latin America Parkinson's Disease (PD) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Middle East and Africa Parkinson's Disease (PD) Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Middle East and Africa Parkinson's Disease (PD) Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Porter's Five Forces Analysis
Figure 119. Channels of Distribution
Figure 120. Distributors Profiles
Figure 121. Bottom-up and Top-down Approaches for This Report
Figure 122. Data Triangulation
Figure 123. Key Executives Interviewed
パーキンソン病治療の世界市場（～2026年） Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. There is no cure for Parkinson's disease, with treatment directed at improving symptoms. Initial treatment is typically with the antiparkinson medication levodopa (L-DOPA…- パーキンソン病の世界市場（～2026年） Market Analysis and Insights: Global Parkinson's Disease Market The global Parkinson's Disease market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Parkinson's Disease Scope and Market Size Parkinson's Disease market is seg…
- 重症筋無力症治療薬の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- クラッベ病治療薬の世界市場（～2026年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…
- メニエール病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Meniere Disease Drugs Market The global Meniere Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Meniere Disease Drugs Scope and Market Size Meniere Disease Drugs marke…